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Abstract
Background Thoracic insufﬁciency syndrome represents
a novel form of postnatal restrictive respiratory disease
occurring in children with early-onset scoliosis and chest
wall anomalies. Expansion thoracoplasty improves lung
volumes in children with thoracic insufﬁciency syndrome;
however, how it affects lung development is unknown.
Questions/purposes Using a rabbit model of thoracic
insufﬁciency syndrome, we evaluated the effect of expan-
sion thoracoplasty on the response of biologic mechanisms
in the alveolar microstructure.
Methods Using archived material from a previous
experiment, 10 4-week-old New Zealand rabbits were
divided into three groups: normal (n = 3), disease (n = 3),
and treated (n = 4). Left ribs four to eight were tethered in
seven rabbits at age 5 weeks to induce hypoplasia of the
left hemithorax (disease). At age 10 weeks, four of these
rabbits were treated by expansion thoracoplasty (treated).
At age 24 weeks, lungs were excised and processed.
Alveolar density and parenchymal airspace were measured
on histologic sections. Immunohistochemistry was per-
formed for vascular endothelial growth factor receptor 2
(angiogenesis), KI-67 (cell proliferation), and RAM-11
(macrophages).
Results Alveolar walls were poorly perfused and airspace
fraction was larger (emphysematous) in disease rabbits
than normal or treated rabbits. Immunohistochemistry
provided inconclusive evidence to support the concept that
pulmonary hypoplasia is induced by thoracic insufﬁciency
syndrome and controlled by expansion thoracoplasty.
Conclusions Treatment of thoracic insufﬁciency syn-
drome by expansion thoracoplasty may prevent
emphysematous changes in the alveolar microstructure,
thereby enhancing gas exchange.
Clinical Relevance Creating an animal model for thoracic
insufﬁciency syndrome should provide insight into the
effect of expansion thoracoplasty on lung development
otherwise clinically unattainable.
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Thoracic insufﬁciency syndrome (TIS) is the inability of
the thorax to support normal respiration and postnatal lung
growth [3, 9]. It reﬂects a novel form of restrictive
respiratory disease and postnatal pulmonary hypoplasia
occurring in children with early-onset scoliosis and
anomalies of the thorax. TIS presumably interferes with
neonatal pulmonary alveolarization, a process that slows
exponentially from birth until it is largely completed
around 5 years of age [6]. A deﬁcit in alveolarization
during this period is thought to be irrecoverable; thus,
urgent intervention may be required in young children to
reduce long-term pulmonary risk [1]. Campbell et al. [2]
pioneered expansion thoracoplasty for the treatment of TIS
using a Vertical Expandable Prosthetic Titanium Rib
(VEPTR
TM; Synthes Inc, West Chester, PA) to lengthen
the constricted hemithorax, simultaneously correcting the
thoracic hypoplasia and associated scoliosis by distracting
open the concavity of the spine and chest wall deformity.
The rationale for this treatment was that in growing chil-
dren, removing the chest wall constriction and lengthening
the thorax would mechanically stretch the lung, thereby
increasing lung volume and stimulating acinar develop-
ment. Clinical studies in children with TIS treated with
VEPTR
TM [2, 4, 8] have demonstrated an increase in total
lung volume and a reduction in scoliosis. However, it
remains unknown how expansion thoracoplasty affects the
growth and development of the lung in affected patients.
The fragile health of children afﬂicted with TIS makes
it technically challenging to systematically evaluate the
interdependence of growth of the spine, thorax, and lung
in vivo. Therefore, we developed a rabbit model that
exhibits some of the clinical features of TIS in a pre-
liminary pilot study [14]; we created a constricted
hemithorax that induced thoracic hypoplasia and scoliosis
in growing rabbits by unilaterally tethering the ribs in
5-week-old rabbits. Using this model in another pilot study
[13], we evaluated how expansion thoracoplasty affected
thoracic volume, lung volume, respiratory mechanics,
alveolar morphology, and spine deformity during growth.
The observations suggested expansion thoracoplasty did
not substantially affect total lung volumes: the volume of
the constricted hemithorax was increased, but the volume
of the ipsilateral lung was not. Expansion thoracoplasty
did improve alveolar histomorphometry (airspace fraction)
and appeared to improve alveolar capillary perfusion,
although we observed no increase in the total number of
alveoli. From that pilot study, we inferred expansion
thoracoplasty may improve pulmonary growth by modi-
fying or preventing the abnormal alveolar structure caused
by experimental TIS. Thus, although expansion thoraco-
plasty improves lung volumes in our model and in
children with TIS, the mechanisms by which it affects
lung development remain unclear.
To assess how expansion thoracoplasty affects biologic
mechanisms, we explored (1) alveolar microstructure
development (proliferating and macrophage cell fractions);
and (2) capillary development and perfusion (vascular
endothelial growth factor receptor 2 [VEGFR-2] immu-
nohistochemistry and red blood cells in eosin-stained
sections).
Materials and Methods
Because a rabbit model for TIS and its treatment by
expansion thoracoplasty had not been previously estab-
lished, our hospital’s Institutional Animal Care and Use
Committee limited the number of rabbits allowed to
undergo the surgical procedures. We therefore examined
archived pulmonary tissue from our previous rabbit model
of TIS [13]; no new experiments were performed. Thus, by
necessity, this is a pilot study; the sample size is small and
the study is underpowered. Descriptions of the surgical
procedures, methods for acquiring lung volumes, and pre-
paring excised lung tissue have been published previously
[13] and therefore are only brieﬂy summarized here.
In our previous study, 10 4-week-old New Zealand
rabbits were divided into three groups: normal (n = 3),
disease (n = 3), and treated (n = 4). Three healthy rabbits
served as a control (normal group). At age 5 weeks,
hypoplasia of the left hemithorax was induced in seven
rabbits by passing a subperiosteal ﬁgure-of-eight ligature
(Ethibond1; Ethicon Inc, Somerville, NJ) posteriorly
around the fourth to eighth left ribs, tethering them together
to create a constricted left hemithorax (Fig. 1). Subse-
quently, four of these seven rabbits were treated by
expansion thoracoplasty (treated group) at age 10 weeks
and three were left untreated (disease group). The fused
Fig. 1 A ﬂow diagram shows an outline of the study.
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123ribs were osteotomized at the apex of the concavity of the
constricted left hemithorax using a dental burr. The tho-
racostomy was then distracted open using sublaminar
hooks from a cervical spine instrumentation system
(CerviFix1; Synthes Inc) to cradle the osteotomized ribs
placed in opposition at either end of a 3.5-mm titanium rod
(Fig. 2). At 24 weeks, all rabbits were ventilated on pure
O2 for 10 minutes before euthanasia. The lungs and heart
were excised and the lungs were inﬁltrated with formalin at
25 mm Hg for 48 hours before being entirely embedded in
parafﬁn. The parafﬁn-embedded lung samples were cut
into 2- 9 2- 9 2-cm tissue blocks selected by stratiﬁed
random sampling [7] and were then cut into 7-lm-thick
tissue sections for histologic examination.
The rabbit is a useful model to understand postnatal
pulmonary development in the human because rabbits have
substantial postnatal alveolar development, which is
thought to decrease at an exponential rate approaching
maturity, similar to humans. Time points in this study were
based on the normal timeline of skeletal maturation and
alveolarization in the rabbit as compared with that of a
human. The rabbit reaches skeletal maturity near 28 weeks
of age, and although there may be some alveolarization
potential through this time, the majority occurs before
16 weeks of age with approximately 25% of total alveoli
present in the 5-week-old rabbit and 50% of total alveoli
present in the 10-week-old rabbit [12]. Thus, after expan-
sion thoracoplasty surgery, 50% of pulmonary growth
potential remains in the growing rabbit. This physiological
time point, measured by alveolar development remaining,
is believed to be equivalent to approximately a 3-year-old
child. The time point for euthanasia was chosen at a point
in time when skeletal and pulmonary growths were both
near completion.
In our previous study [13], alveolar number density
(number of alveoli per unit of volume) was determined for
the left and right lungs as described by Weibel and Gomez
[21], and parenchymal airspace fraction was measured
separately for each of the ﬁve lobes in rabbit lungs as
described by Dunnill [7]. Morphometric analysis was per-
formed by two independent reviewers (MJH, SRB) on
hematoxylin and eosin-stained slides; interobserver vari-
ability was determined through regression and correlation
(slope = 0.86; correlation coefﬁcient = 0.71).
Immunohistochemistry (Table 1) was performed using
antibodies against VEGFR-2, thyroid transcription factor 1
(TTF-1), macrophage-speciﬁc antigen (RAM-11), and
KI-67 cell proliferation marker. Quantiﬁcation was per-
formed through cell fraction but only on macrophage and
KI-67; VEGFR-2 stains were not localized enough to dis-
tinguish individually expressing cells and are displayed as
a double stain with TTF-1 for insight on colocalization.
Previous morphologic analysis of excised lung tissue
from our TIS rabbit model [13] demonstrated the left upper
lobe (LUL) was modiﬁed the most, whereas the right lower
lobe (RLL) was modiﬁed the least and could serve as an
Fig. 2A–C Three-dimensional
CT reconstructions depict each
experimental group: (A) a tho-
racic insufﬁciency syndrome
(TIS) disease rabbit displaying
fused ribs with a constricted left
hemithorax; (B) a treated rabbit
after expansion thoracoplasty of
the left hemithorax; and (C)a
normal healthy rabbit.
Table 1. Antibodies used in immunohistochemistry
Antibody Identiﬁes Company (catalog number) Primary concentration
(time)
Antigen retrieval
VEGFR-2 Angiogenesis signaling Santa Cruz Biotechnology Inc,
Santa Cruz, CA (6251)
1:200 (1 hour) Citrate at 125C for 3 minutes
TTF-1 Type II pneumocytes DAKO, Carpinteria, CA (M3575) 1:150 (1 hour) Citrate at 125C for 3 minutes
KI-67 Proliferating cells DAKO (M7240) 1:500 (1 hour) Citrate at 125C for 3 minutes
RAM-11 Macrophage cells DAKO (M0633) 1:100 (1 hour) Citrate at 90C for 40 minutes
VEGFR-2 = vascular endothelial growth factor receptor 2; TTF-1 = thyroid transcription factor 1.
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123internal control to understand the heterogeneity of biology
within each group of animals. Therefore, only samples from
the LUL and RLL of each animal were evaluated by
immunohistochemistry. For each antibody stain in each
rabbit, three sections with at least 100-lm intervening dis-
tance between them were analyzed. The lung sections were
deparafﬁnized, rehydrated, and then immersed in citrate
solution, pH 6.0, for epitope retrieval at either 90C for 40
minutes or 125C for 3 minutes in a pressure cooker. We
visualized three single-stained sections with a peroxidase
immunoenzyme labeling kit (Vectastain1 Elite1 ABC;
Vector Laboratories Inc, Burlingame, CA) and developed in
3,30-diaminobenzidine (DAB) substrate. Double-stained
VEGFR-2/TTF-1 sections were stained sequentially using
the peroxidase labeling kit developed with NovaRED
TM
substrate (Vector Labs) and then an alkaline phosphatase
labeling kit (Vectastain1 ABC-AP kit; Vector Labs) with
Vector1 Blue substrate (Vector Labs). Crossreactivity
between VEGFR-2 and TTF-1 antibodies (both mouse
monoclonal) was inhibited using an additional mouse
antibody blocking protocol between sequential stainings
(Vector1 M.O.M.
TM basic kit; Vector Labs). Endogenous
peroxidase activity was blocked before the primary anti-
body application using a 3% hydrogen peroxide solution for
10 minutes. All single stains were counterstained with
hematoxylin and double stains had no counterstain.
For each of the stained tissue sections from each animal,
ﬁve digital images were acquired at random by overlaying
a grid of 1- 9 1-mm squares, numbered sequentially, and
picking ﬁvenumbers usingarandomnumbergenerator.The
image at that location was then magniﬁed (9200). Cell
counting was automated using a color deconvolution pro-
gram [15] and MATLAB1 functions in the Image
Processing toolbox (The MathWorks Inc, Natick, MA).
Immunohistochemistry signals for macrophages and KI-67-
positive cells were quantiﬁed in the alveolar space by
counting the number of positively labeled cells normalized
bythetotalnumberofcellswithhematoxylin-stainednuclei.
VEGFR-2/TTF-1 was not quantiﬁed in this manner because
individual positively labeled cells could not be discerned;
rather, they were examined for qualitative differences based
on the intensity of the stain in the alveolar space.
Differences in alveolar cell counts of macrophages and
KI-67-positive proliferating cells were determined between
all experimental groups (normal, disease, and treated
groups) using analysis of variance and Fisher’s probable
least signiﬁcant difference by post hoc analysis. Qualitative
observations were made of VEGFR-2/TTF-1 slides and
hematoxylin and eosin-stained slides. We used Sigmaplot
(Systat Software Inc, San Jose, CA) for all analyses.
Results
We could make no deﬁnite inference of whether expansion
thoracoplasty inﬂuenced alveolar microstructure develop-
ment based on a reduced number of macrophages (LUL:
F = 1.00, p = 0.43; RLL: F = 0.38, p = 0.70) (Fig. 3)o r
Fig. 3A–D Images illustrate the
immunohistochemistry of lung
tissue for antibody against
RAM-11 (macrophage) in the
three study groups: (A) disease
lung, (B) normal lung, and (C)
treated lung. RAM-11-positive
cells are brown (3,30-diam-
inobenzidine) and cell nuclei
blue (hematoxylin) (original
magniﬁcation, 9200). (D) Posi-
tively stained cells were counted
and are given as a percentage of
total cell number. The left upper
lobe (LUL) of disease rabbits
had insigniﬁcantly higher cell
counts. Sections from the right
lower lobe (RLL) also show high
variability. Error bars = 1 SD.
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123an increased number of KI-67-positive proliferating cells
(LUL: F = 3.04, p = 0.16; RLL: F = 1.39, p = 0.33)
(Fig. 4) for both the LUL and the RLL. This is most likely
the result of the study being underpowered.
Qualitative evaluation of histologic sections showed
emphysematous dilated alveoli and an apparent reduction
in red blood cells suggested poor perfusion of alveolar
walls. This was particularly noticeable in the LUL (Fig. 5)
closest to the rib fusion but also in the left lower lobe
(LLL). The alveolar morphology was more normal in
appearance in the treated lungs; red blood cells were
abundant throughout the thicker alveolar walls. VEGFR-2-
stained cells appeared less abundant in disease lungs than
in treated and normal lungs. VEGFR-2-stained cells
showed frequent colocalization with Type II pneumocytes,
identiﬁed by TTF-1 double stains (Fig. 6). Endothelial,
macrophage, and bronchial epithelial cells were also
positive for VEGFR-2.
Discussion
TIS represents a novel form of postnatal pulmonary
hypoplasia and restrictive respiratory disease that occurs in
children with early-onset scoliosis and chest wall anoma-
lies. Expansion thoracoplasty improves thoracic volume in
children with TIS; however, how it affects the growth and
development of the lung is unknown. We presume thora-
coplasty modiﬁes the growth and development of the lung,
improving alveolar structure, which may ultimately
improve the ability of the lungs for gas exchange. In this
study, we assessed how expansion thoracoplasty affects
biologic mechanisms related to (1) development of the
alveolar microstructure through cell fraction analysis of
proliferating cells and macrophage; and (2) capillary
development and perfusion through qualitative assessment
of VEGFR-2 immunohistochemistry and hematoxylin and
eosin-stained sections.
Although this pilot study was noteworthy for establish-
ing the ﬁrst animal model to explore the growth and
development of lungs subjected to a constricted hemithorax
and its subsequent reversal by expansion thoracoplasty,
there are several limitations. First, the sample size was
small and the study was underpowered as a result of
restrictions placed by our institutional animal review
committee until feasibility of the methods was proven.
Nevertheless, some important themes were observed that
provide insight as to how thoracic insufﬁciency might
affect the development of the growing lung and how
expansion thoracoplasty might compensate for these
changes. Second, the rabbit model did not reproduce the
severe pulmonary and spinal abnormalities seen clinically
in children with TIS. Even so, interesting results were
found from histologic evaluation, which can inform on the
consequence of thoracic deformity on pulmonary devel-
opment in clinical cases. Third, the lack of accelerated lung
growth and reduction in alveolar density after expansion
thoracoplasty may reﬂect surgical trauma (pneumothorax,
Fig. 4A–D Images illustrate the
immunohistochemistry of lung
tissue for KI-67 antibody (prolif-
eration marker) in the three study
groups: (A) disease lung, (B)
normal lung, and (C) treated
lung. KI-67-positive cells are
brown (3,30-diaminobenzidine)
and cell nuclei blue (hematoxylin)
(original magniﬁcation, 9200).
(D) Positively stained cells were
counted and are given as a per-
centage of total cell number. The
number of proliferating cells
(KI-67-positive) was insigniﬁ-
cantly decreased in the left
upper lobe (LUL) of disease
lungs compared with both
treated and normal lungs. Similar
numbers of KI-67-positive cells
were observed among the groups
for the right lower lobe (RLL).
Error bars = 1 SD.
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123pleural scarring). We used the right lower lobe as a control
rather than a sham surgery control group to identify the
degree of iatrogenic effects. This control has the advantage
of controlling for interanimal differences but has the dis-
advantage of not being from a sham surgery control
animal. Last, although immunohistochemistry provided
useful insights as to the factors contributing to lung
development, the technique is essentially qualitative;
quantitative expression assays may have been more
informative.
In our current evaluation, we expected a reduced pro-
liferating cell fraction would co-occur with the
emphysematous alveolar structure and increased airspace
fraction [13] found in disease rabbit lungs. A reduction in
KI-67-immunopositive proliferating cells is characteristic
of hypoplastic lung tissue [18]. Conversely, an increased
proliferating cell fraction in treated rabbits would imply
active remodeling of the alveolar morphology, including
growth of the capillary network. However, our study is
inconclusive on these points, most likely as a result of
small sample sizes. These changes would improve respi-
ratory function in rabbits treated with expansion
thoracoplasty by facilitating CO2-O2 gas exchange. Similar
respiratory compensation through alveolar remodeling has
been observed in postpneumonectomy animal models [10,
17]. Measurements of alveolar macrophage abundance had
high variance and no conclusion on relative abundance
between experimental groups can be made. Macrophages
phagocytize cellular debris and might have an excess
presence in disease lungs as a result of infection or necrotic
tissue.
Cellular signaling through the VEGF pathway [20]i sa
positive regulator of angiogenesis and capillary formation
and an important precursor to the alveolarization phase of
lung development [5, 6, 11]. We speculate an increase in
capillary development and VEGFR-2 [16] abundance is
present after expansion thoracoplasty; however, our
immunohistochemistry results are not quantitative.
Fig. 5A–F Representative his-
tologic images of the left upper
lobe (LUL) are shown for each
experimental group (stain, hema-
toxylin and eosin). (A–C) Wide-
ﬁeld images (original magniﬁca-
tion, x200) display the relatively
large airspaces in the (A) disease
lung compared with the (B)
treated and (C) normal lung.
(D–F) Higher magniﬁcation (ori-
ginal magniﬁcation, x400) shows
relatively poorly perfused alveo-
lar walls in the (D) disease lung
compared with the (E) treated
and (F) normal lung (red blood
cells are bright pink). (E)T r e a t e d
lung tissue shows enhanced
perfusion and smaller alveolar
spaces.
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123The increased presence of red blood cells observed in
hematoxylin and eosin-stained sections was conspicuous
in the LUL of expansion thoracoplasty-treated rabbits
(compared with disease rabbits), suggesting an enhanced
alveolar capillary network. Either change will enhance the
capacity of the lungs for gas exchange. In experimental
studies of bronchopulmonary dysplasia in rats [19], ther-
apy with nitric oxide improved the structure of the lung
by inducing vasodilatation and enhancing pulmonary
perfusion. Conversely, a long-term clinical followup study
of adults with pulmonary hypoplasia induced by early-
onset scoliosis [9] demonstrated a reduction in the
capacity for pulmonary gas exchange. Therefore, the
enhanced perfusion observed in rabbits treated with
expansion thoracoplasty may signal the initiation of
alveolar remodeling.
It is currently unknown whether expansion thoraco-
plasty improves respiratory function and/or respiratory
growth and by what mechanisms. Despite its limitations,
this study suggests further hypotheses that should be tested
in a future statistically powered study. Such a study will be
vital to answer questions on how postnatal timing of
intervention with expansion thoracoplasty affects the
mechanism of long-term pulmonary development (alveo-
larization). Clinical pulmonary biopsies are difﬁcult to
obtain from pediatric patients with TIS and suitable control
groups are unavailable; therefore, this model has great
value in the study of TIS and expansion thoracoplasty
intervention.
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